SSTR3
Somatostatin receptor type 3
As of the edition of 20 October 2026, SSTR3 (somatostatin receptor type 3, UniProt P32745) has 9 drugs tested at it and 15 companies on the list, 2 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P32745
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Cancer; Hormones; Digestive system; Nervous system; Bones, joints and muscles; Nutrition and metabolism; Urinary and reproductive; Blood and lymph
- Registered trials of its drugs
- 335
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 2 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Octreotide | Marketed | Phase 4 | none listed |
| Pasireotide | Marketed | Phase 4 | Ends 2026 |
| Lutetium oxodotreotide | Marketed | Phase 4 | Ends 2031 |
| Somatostatin | Marketed | Phase 4 | none listed |
| ITF2984 | Went quiet | Phase 2 | none listed |
| Indium pentetreotide | Marketed | Phase 4 | none listed |
| DOTA-NOC | Went quiet | Phase 3 | none listed |
| Lutetium-177 | Status not established | No phase stated | none listed |
| Lutetium chloride | Withdrawn from market | No phase stated | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 4 |
| Engaged | 4 |
| Undetermined | 5 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Curium | Route B |
| Camurus | Route B |
| ITM Medical Isotopes | Route A |
The other 12 companies at SSTR3
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at SSTR3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.